NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...
manilatimes3d
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...
TMCnet11h
CRBU Deadline: Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between ...
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...
INmune Bio, Inc.: INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of “Buy” from Analysts
Shares of Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...
The Victoria Advocate15d
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit
So what: If you purchased Caribou securities during the Class Period you ... research activities associated with the allogeneic CAR-NK platform; (3) the foregoing was likely to have a significant ...